Dimitrios A. Pappas

Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis

Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis

A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study

TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study

Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients

Real‐World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor

Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis

AB0244 Development of an adjusted multi-biomarker disease activity (MBDA) score for rheumatoid arthritis (RA) that accounts for age, sex and adiposity, with subsequent evaluation of ability to predict risk for radiographic damage

Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme

Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis

Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease

Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry

TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease‐Modifying Antirheumatic Drugs

Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes

How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries

Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene

High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci

Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients

Genetics of rheumatoid arthritis contributes to biology and drug discovery

Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease

Brief Report: Identification of <i>BACH2</i> and <i>RAD51B</i> as Rheumatoid Arthritis Susceptibility Loci in a Meta‐Analysis of Genome‐Wide Data

Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients